Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects with Type 2 Diabetes Mellitus(DURATION - 1)

Exclusion Criteria

• - Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog.
• - Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
• - Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
• * Alpha glucosidase inhibitor or meglitinide within 30 days of screening;
• * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
• * Regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
• * Regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
• * Regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
• * Prescription or over-the-counter weight loss medications within 6 months of screening.
• - (For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy